Arthi Reddy

Arthi Reddy

From The Division Of Pediatric Rheumatology, Morgan Stanley Children's Hospital Of New York-Presbyterian Hospital/columbia University Medical Center; New York University ...

Direct Impact

Concepts for which Arthi Reddy has direct influence:

systemic lupus erythematosus
6 months
academic practices
organ systems
monoclonal antibody
childhood-onset sle
iii trials

Prominent publications by Arthi Reddy

KOL-Index: 9 Belimumab (Benlysta) is a human monoclonal antibody that inhibits soluble B-Lymphocyte Stimulator and improves SLE disease activity. This study was initiated to evaluate the use and efficacy of Belimumab in academic SLE clinical practices. An invitation to participate was sent to 16 physicians experienced in SLE Phase III clinical trials. All agreeing to participate completed a one page ...
Known for
Improvement Arthritis
KOL-Index: 3 OBJECTIVE: To evaluate the use and efficacy of belimumab in academic practices. Belimumab is a human monoclonal antibody that inhibits soluble B lymphocyte stimulator and has been approved for the treatment of adults with systemic lupus erythematosus (SLE). METHODS: Invitations to participate and complete a 1-page questionnaire for each patient prescribed belimumab were sent to 16 physicians ...
Known for
Erythematosus Sle | Improvement Childhood | Months Responded | Treated Belimumab

From the Division of Pediatric Rheumatology, Morgan Stanley Children's Hospital of New York-Presbyterian Hospital/Columbia University Medical Center; New York University Langone Medical Center; Division of Rheumatology, New York-Presbyterian Hospital

https://www.g2.com/products/key-opinion-leaders-kols/reviews https://www.bbb.org/us/fl/doral/profile/data-analytics/key-opinion-leaders-0633-92023858 https://www.trustpilot.com/review/keyopinionleaders.com https://www.yelp.com/biz/key-opinion-leaders-miami


© 2022 - Key Opinion Leaders -
Key Opinion Leaders, LLC ,
2025 NW 102 Avenue, Suite 111 Doral , FL   33172